According to the amended complaint, University of Utah's Brenda Bass had “so well-defined” the concept at issue that it "could have been reduced to practice by someone with ordinary skill in the art without further research.”
Alnylam said that as part of the agreement, it would allow Merck, the parent company of one-time rival Sirna Therapeutics, to sub-license a portion of the disputed IP to which it previously did not have access.
The company said this week that it has begun manufacturing prototype disposable test cartridges for performing rapid, inexpensive PCR assays as part of a future portable HIV detection and monitoring system for use in developing countries.
While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.
BioServe touts the repository as the "the largest resource of high-quality biosamples for the life science industry" and claims that researchers can access it to garner biosamples from "most any major diseases."